Alyeska Investment Group
TNGX icon

Alyeska Investment Group’s Tango Therapeutics TNGX Stock Holding History

Alyeska Investment Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6M Buy
691,109
+673,911
+3,919% +$16.7M 0.06% 325
2026
Q1 		$360K Buy
+17,198
New +$239K ﹤0.01% 594
2023
Q3 		– Sell
-74,338
Closed -$247K – 624
2023
Q2 		$247K Hold
74,338
– – ﹤0.01% 521
2023
Q1 		$294K Hold
74,338
– – ﹤0.01% 429
2022
Q4 		$539K Hold
74,338
– – 0.01% 370
2022
Q3 		$269K Hold
74,338
– – ﹤0.01% 373
2022
Q2 		$337K Hold
74,338
– – ﹤0.01% 539
2022
Q1 		$563K Sell
74,338
-50,000
-40% -$433K 0.01% 541
2021
Q4 		$1.36M Sell
124,338
-300,300
-71% -$3.61M 0.02% 491
2021
Q3 		$5.49M Sell
424,638
-9,455
-2% -$113K 0.07% 305
2021
Q2 		$4.94M Sell
434,093
-8,219
-2% -$92.3K 0.06% 352
2021
Q1 		$4.92M Sell
442,312
-57,688
-12% -$663K 0.06% 332
2020
Q4 		$5.72M Sell
500,000
-4,000
-0.8% -$42.1K 0.08% 252
2020
Q3 		$5.22M Buy
+504,000
New +$5.15M 0.08% 257

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Alyeska Investment Group's TNGX Position: Q2 2026 in Review

Alyeska Investment Group increased its Tango Therapeutics (TNGX) stake by 3,919% in Q2 2026, buying an estimated $16.7M and bringing the position to 691,109 shares worth $21.6M. The position accounts for 0.06% of the portfolio, ranked #325.

Alyeska Investment Group first reported a position in TNGX in Q3 2020 and has held it in 14 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Alyeska Investment Group held 691,109 shares of Tango Therapeutics worth $21.6M as of Q2 2026.
  • Alyeska Investment Group bought 673,911 Tango Therapeutics shares in Q2 2026, an estimated $16.7M.
  • Tango Therapeutics made up 0.06% of Alyeska Investment Group's portfolio in Q2 2026, its #325 holding.
  • Alyeska Investment Group first reported a position in Tango Therapeutics in Q3 2020 and has held it in 14 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.